Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Still a Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped up prior to trading on Wednesday . The stock had previously closed at $35.15, but opened at $36.05. Nanobiotix shares last traded at $35.7960, with a volume of 7,275 shares traded.

Analyst Ratings Changes

NBTX has been the topic of several analyst reports. Leerink Partners raised their price target on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Finally, Guggenheim assumed coverage on shares of Nanobiotix in a research report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.67.

Nanobiotix Stock Down 0.4%

The business has a fifty day moving average price of $39.00 and a two-hundred day moving average price of $37.38.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.